EUVIMEDEUVIMED entdecken
Crossref

Thymoquinone reversed doxorubicin resistance in U87 glioblastoma cells via targeting PI3K /Akt/ mTOR signaling

Mohammad Shimia, Monireh Amini, Armin Ostovar Ravari, Peyman Tabnak, Amir Valizadeh, Mohammad Ghaheri, Bahman Yousefi iD

Chemical Biology & Drug Design · 2024

DOI: 10.1111/cbdd.14587 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Chemical Biology & Drug Design, 2024. Verfasst von Mohammad Shimia und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran. Hauptthemen laut MEDLINE: Doxorubicin, TOR Serine-Threonine Kinases, Benzoquinones, Proto-Oncogene Proteins c-akt. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 31 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Natural compounds such as thymoquinone (TQ) have recently gained increasing attention in treating glioblastoma (GBM). However, the effects of TQ in reversing drug resistance are not completely understood. Therefore, we aimed to examine TQ impacts on GBM cells with doxorubicin (DOX) resistance and the involvement of the PI3K/Akt/mTOR pathway. GBM cancer U87 and U87/DOX (resistant cells) cells were exposed to DOX and TQ, and cell proliferation was assessed by the MTT assay. ELISA was applied to evaluate cell apoptosis. The expression of apoptotic mediators such as Caspase‐3, Bax, Bcl‐2 and PI3K, Akt, mTOR, P‐gp, and PTEN was assessed via qRT‐PCR and western blot. We found that a combination of TQ and DOX suppressed dose‐dependent cell growth capacity in cells and increased the cytotoxic effects of DOX in resistant cells. In addition, TQ treatment increased DOX‐mediated apoptosis in U87/DOX cell lines via modulating the pro‐ and anti‐apoptotic markers. A combination of TQ and DOX upregulated PTEN and downregulated PI3K, Akt, and mTOR, suppressing this signal transduction in resistant cells. In conclusion, we showed TQ potentiated doxorubicin‐mediated antiproliferative and pro apoptotic function DOX‐resistant glioblastoma cells, which is mediated by targeting and suppressing PI3K/Akt/mTOR signal transduction.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DoxorubicinTOR Serine-Threonine KinasesBenzoquinonesProto-Oncogene Proteins c-aktGlioblastomaSignal TransductionDrug Resistance, NeoplasmPhosphatidylinositol 3-KinasesApoptosisHumansCell Line, TumorCell Proliferation

Stichwörter der Autor:innen

PI3K/Akt/mTOR pathwayapoptosisdoxorubicin resistanceglioblastomathymoquinone

Substanzen

thymoquinoneDoxorubicinTOR Serine-Threonine KinasesBenzoquinonesProto-Oncogene Proteins c-aktPhosphatidylinositol 3-KinasesMTOR protein, human

Autor:innen und Institutionen

  • Department of Neurosurgery, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.
  • Department of Clinical Biochemistry and Laboratory Medicine, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.
  • Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran.

ORCID-Profile: Bahman Yousefi

Zitieren

APA

Shimia, M., Amini, M., Ravari, A. O., Tabnak, P., Valizadeh, A., Ghaheri, M., & Yousefi, B. (2024). Thymoquinone reversed doxorubicin resistance in U87 glioblastoma cells via targeting PI3K /Akt/ mTOR signaling. Chemical Biology & Drug Design. https://doi.org/10.1111/cbdd.14587

Vancouver

Shimia M, Amini M, Ravari AO, Tabnak P, Valizadeh A, Ghaheri M, et al. Thymoquinone reversed doxorubicin resistance in U87 glioblastoma cells via targeting PI3K /Akt/ mTOR signaling. Chemical Biology & Drug Design. 2024. doi:10.1111/cbdd.14587

BibTeX
@article{Shimia2024,
  author = {Shimia, Mohammad and Amini, Monireh and Ravari, Armin Ostovar and Tabnak, Peyman and Valizadeh, Amir and Ghaheri, Mohammad and Yousefi, Bahman},
  title = {Thymoquinone reversed doxorubicin resistance in U87 glioblastoma cells via targeting PI3K /Akt/ mTOR signaling},
  journal = {Chemical Biology & Drug Design},
  year = {2024},
  doi = {10.1111/cbdd.14587}
}
Kostenlos starten →